文献速递淋巴瘤

正电子发射断层扫描引导的维布妥昔单抗联合依托泊苷、环磷酰胺、多柔比星、达卡巴嗪和地塞米松治疗老年晚期经典霍奇金淋巴瘤:德国霍奇金研究组HD21试验的前瞻性、多中心、单臂、II期队列

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.
PubMed 文献 · J Clin Oncol · 2025-07-17

这项前瞻性、多中心、单臂II期队列纳入85例61-75岁晚期经典霍奇金淋巴瘤患者,评估PET引导的BrECADD方案可行性及疗效。83例可分析患者中,68例(82%;95%CI 72-90)化疗结束时达完全缓解,2年无进展生存率和总生存率分别为91.5%和90.8%,未发生治疗相关死亡。

要点

  • PET2阴性者接受4周期BrECADD,阳性者接受6周期,71例(89%)完成目标周期数。
  • 化疗结束时完全缓解率为82%(95%CI 72-90),2年PFS为91.5%,OS为90.8%。
  • ≥3级毒性以白细胞减少(96%)、血小板减少(86%)、贫血(69%)和发热性中性粒细胞减少(55%)常见。

核心结论

  • PET引导的BrECADD在老年晚期经典霍奇金淋巴瘤患者中可行且有效,2年PFS与年轻患者相当,疗程短且蒽环类暴露有限,是老年患者的有价值治疗选择。

研究设计与样本

  • 德国霍奇金研究组HD21试验的前瞻性、多中心、单臂、II期队列,纳入61-75岁晚期经典霍奇金淋巴瘤患者。
  • 2020年6月至2023年4月共入组85例,83例纳入意向治疗分析,中位年龄67岁(范围61-75)。
  • PET2阴性者接受4周期BrECADD,PET2阳性者接受6周期BrECADD。
  • 主要终点为化疗结束时中心审查的完全缓解率,次要终点包括可行性、不良事件、治疗相关并发症、PFS、OS和健康相关生活质量。

主要发现

  • 80例中心审查PET2的患者中,48例(60%)计划接受4周期BrECADD,32例(40%)接受6周期。
  • 71例(89%)接受了目标周期数。
  • 68例(82%;95%CI 72-90)在化疗结束时达到完全缓解。
  • 2年PFS为91.5%(95%CI 85-98),2年OS为90.8%(95%CI 84-98)。
  • 无死亡归因于研究治疗;初始受损的健康相关生活质量评分在随访中改善并平均达到人群参考值。

关键数值与推荐

  • ≥3级毒性:白细胞减少80例(96%),血小板减少71例(86%),贫血57例(69%),发热性中性粒细胞减少46例(55%)。

临床怎么用

  • 作者认为,PET引导的BrECADD在老年晚期经典霍奇金淋巴瘤患者中可行且有效,是值得考虑的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Positron emission tomography (PET)-guided therapy with 4-6 cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) is highly effective in younger patients with advanced-stage classic Hodgkin lymphoma (AS-cHL). We report feasibility and efficacy of PET-guided BrECADD as first-line treatment in older patients with AS-cHL. PATIENTS AND METHODS: Patients with AS-cHL aged 61-75 years were enrolled in a phase II single-arm cohort of the HD21 trial (ClinicalTrials.gov identifier: NCT02661503). Patients with negative PET/computed tomography after 2×BrECADD (PET2) received a total of 4×BrECADD, while PET2-positive patients received 6×BrECADD. The primary end point was the centrally reviewed complete remission (CR) rate after the end of chemotherapy (EOC). Secondary end points included feasibility, adverse events, treatment-related morbidity (TRMB), progression-free survival (PFS), overall survival (OS), and health-related quality of life (HRQoL). RESULTS: Between June 2020 and April 2023, 85 patients were enrolled, of whom 83 with a median age of 67 years (range, 61-75) were analyzed in the intention-to-treat cohort. Most prevalent ≥grade 3 toxicities included leukopenia (n = 80 [96%]), thrombocytopenia (n = 71 [86%]), anemia (n = 57 [69%]), and febrile neutropenia (n = 46 [55%]). Forty-eight (60%) of 80 patients with centrally reviewed PET2 were scheduled for 4×BrECADD and 32 (40%) for 6×BrECADD. Of these, 71 patients (89%) received the target number of cycles. Sixty-eight patients (82%; 95% CI, 72 to 90) achieved CR at EOC. PFS and OS estimates at 2 years were 91.5% (95% CI, 85 to 98) and 90.8% (95% CI, 84 to 98), respectively. No death was attributed to study treatment. Initially, impaired HRQoL scores improved during follow up and on average reached population reference values. CONCLUSION: PET-guided BrECADD in older patients is feasible and effective. With a PFS rate on par with that of younger patients, short duration, and limited anthracycline exposure, BrECADD is a valuable treatment option also for older patients with AS-cHL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ferdinandus J, Kaul H, Fosså A, et al. Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. J Clin Oncol. 2025. PMID: 40674676. doi:10.1200/JCO-25-00439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。